Equities research analysts at Barclays PLC started coverage on shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) in a note issued to investors on Thursday. The firm set an “overweight” rating and a $45.00 price target on the biopharmaceutical company’s stock. Barclays PLC’s price objective suggests a potential upside of 24.48% from the company’s current price. CLCD […]
